Titan Pharmaceuticals Inc. (TTNP)

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2018 Results - Earnings Call Transcript
April 2, 2019 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q1 2018 Results - Earnings Call Transcript
May 16, 2018 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2017 Results - Earnings Call Transcript
April 2, 2018 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q3 2017 Results - Earnings Call Transcript
Nov. 9, 2017 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q2 2017 Results - Earnings Call Transcript
Aug. 9, 2017 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q1 2017 Results - Earnings Call Transcript
May 12, 2017 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2016 Results - Earnings Call Transcript
March 16, 2017 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q3 2016 Results - Earnings Call Transcript
Nov. 9, 2016 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q2 2016 Results - Earnings Call Transcript
Aug. 9, 2016 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q1 2016 Results - Earnings Call Transcript
May 10, 2016 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2015 Results - Earnings Call Transcript
March 15, 2016 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals (TTNP) Q3 2015 Results - Earnings Call Transcript
Nov. 16, 2015 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) Q2 2015 Results - Earnings Call Transcript
Aug. 17, 2015 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
May 14, 2015 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
April 1, 2015 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals (TTNP) Q3 2014 Results - Earnings Call Transcript
Nov. 14, 2014 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals (TTNP) Q2 2014 Results - Earnings Call Transcript
Aug. 14, 2014 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals (TTNP) Q1 2014 Results - Earnings Call Transcript
May 15, 2014 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' Management Discusses Q4 2013 Results - Earnings Call Transcript
April 1, 2014 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 15, 2013 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' Management Presents at Update Conference (Transcript)
Nov. 13, 2013 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' Management Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 15, 2013 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
May 16, 2013 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' Management Discusses Q4 2012 Results - Earnings Call Transcript
March 18, 2013 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' CEO Discusses Q3 2012 Earnings Results - Earnings Call Transcript
Nov. 13, 2012 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Aug. 14, 2012 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Nov. 11, 2008 | Price: Free! | Source: Seeking Alpha

Titan Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Sept. 23, 2008 | Price: Free! | Source: Seeking Alpha

Recent filings

Registration statement under Securities Act of 1933 - April 16, 2019

Registration statement under Securities Act of 1933 - April 5, 2019

Titan Pharmaceuticals Inc.'s President and CEO was just granted 200,000 options - April 3, 2019

Departure of Directors or Certain - April 3, 2019

Titan Pharmaceuticals Inc.'s Executive Chairman was just granted 200,000 options - April 3, 2019

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: 14. Subsequent Event... - April 2, 2019

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: 14. Subsequent Event... - April 1, 2019

Titan Pharmaceuticals Inc.'s See Remarks just declared 41,667 options - Feb. 25, 2019

Titan Pharmaceuticals Inc.'s Chief Scientific Officer just declared owning 2,387 shares of Titan Pharmaceuticals Inc. - Feb. 25, 2019

Departure of Directors or Certain - Feb. 25, 2019

Regulation FD - Feb. 14, 2019

Titan Pharmaceuticals Announces Reverse Stock Split - Jan. 25, 2019

Titan Pharmaceuticals Inc. releases salary data. CEO sees compensation fall -16% - Dec. 20, 2018

Other preliminary proxy statements - Dec. 6, 2018

Titan Pharmaceuticals Inc. director just picked up 200,000 shares - Oct. 22, 2018

Current report, item 8.01 - Oct. 22, 2018

On October - Oct. 3, 2018

Titan Pharmaceuticals Inc. director just picked up 500,000 shares - Sept. 26, 2018

Titan Pharmaceuticals Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Sept. 25, 2018

Titan Pharmaceuticals Prices $9,500,000 Public Offering - Sept. 25, 2018

Titan Pharmaceuticals Inc. director just picked up 200,000 shares - Sept. 25, 2018

Titan Pharmaceuticals Inc. director just picked up 200,000 shares - Sept. 25, 2018

Titan Pharmaceuticals Inc.'s Executive Chairman just picked up 400,000 shares - Sept. 25, 2018

Titan Pharmaceuticals Inc. director just picked up 80,000 shares - Sept. 25, 2018

Titan Pharmaceuticals Inc.'s See Remarks just picked up 300,000 shares - Sept. 25, 2018

Prospectus [Rule 424(b)(5)] - Sept. 24, 2018

Creation of Direct Financial Obligation or an Obligation under an - Sept. 20, 2018

General form for registration of securities under the Securities Act of 1933 - Sept. 20, 2018

Titan Pharmaceuticals Inc. Just Received a Notice of Effectiveness - Sept. 20, 2018

General form for registration of securities under the Securities Act of 1933 - Sept. 12, 2018

Titan Pharmaceuticals: Titan Awarded Nida Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse - Sept. 10, 2018

Filing under Securities Act Rules 163/433 of free writing prospectuses - Sept. 10, 2018

Titan Pharmaceuticals: Titan And The Nevada Center For Behavioral Health Collaborate To Evaluate Probuphine® Treament Of Oud Patients Within The State Of Nevada Criminal Justice System - Sept. 4, 2018

Filing under Securities Act Rules 163/433 of free writing prospectuses - Sept. 4, 2018

General form for registration of securities under the Securities Act of 1933 - Aug. 30, 2018

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - Aug. 17, 2018

General form for registration of securities under the Securities Act of 1933 - Aug. 14, 2018

Submission of Matters to a Vote of Security - Aug. 8, 2018

Titan Pharmaceuticals: Titan Announces Amendment To Agreement With Molteni - Aug. 3, 2018

On July - July 31, 2018

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - June 1, 2018

Titan Pharmaceuticals And Braeburn Announce Mutual TERMINATION OF LICENSE AGREEMENT FOR PROBUPHINE® FOR OPIOID DEPENDENCE - May 30, 2018

Titan Pharmaceuticals Inc. director just declared owning 100,845 shares of Titan Pharmaceuticals Inc. - May 23, 2018

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - April 13, 2018

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: The following ta... - April 2, 2018

Confidential treatment order - April 2, 2018

Titan Pharmaceuticals: Titan Executes Agreement For Acquisition By Molteni Of PROBUPHINE IN EUROPE AND OTHER SELECT TERRITORIES - March 26, 2018

Titan Pharmaceuticals Inc.'s President and CEO was just granted 170,000 options - March 9, 2018

Titan Pharmaceuticals Inc.'s Executive Chairman was just granted 170,000 options - March 9, 2018

Robert E. Mead just provided an update on share ownership of Titan Pharmaceuticals Inc. - Feb. 8, 2018

Titan Pharmaceuticals: Titan Announces Amendment To Horizon Loan Agreement - Feb. 7, 2018

Titan Pharmaceuticals: Titan In Discussions With Braeburn Regarding U.S PROBUPHINE COMMERCIALIZATION - Jan. 22, 2018

Titan Pharmaceuticals © 2018 Titan Pharmaceuticals Inc. | Nasdaq:Ttnp Corporate Presentation | January 2018 - Jan. 8, 2018

Confidential treatment order - Dec. 7, 2017

Titan Pharmaceuticals Partners With Molteni To Market Probuphine IN EUROPE - Nov. 28, 2017

Titan Pharmaceuticals Inc. Just Filed Its Quarterly Report: 3. Net Income (Loss... - Nov. 9, 2017

Titan Pharmaceuticals Inc. Just Received a Notice of Effectiveness - Nov. 8, 2017

Registration statement under Securities Act of 1933 - Nov. 6, 2017

Registration statement under Securities Act of 1933 - Oct. 26, 2017

First Patient Treated With Titan Pharmaceuticals' SUBDERMAL IMPLANT FOR PARKINSON'S DISEASE - Oct. 12, 2017

Titan Pharmaceuticals And Opiant Pharmaceuticals Collaborate To Explore A New Approach To Opioid Use Disorder Treatment - Oct. 2, 2017

© 2017 Titan Pharmaceuticals Inc. | Nasdaq:Ttnp Corporate Presentation | September 2017 Titan Pharmaceuticals - Sept. 21, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Sept. 19, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Sept. 19, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Sept. 19, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Sept. 19, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Sept. 19, 2017

Titan Pharmaceuticals Receives Fda Clearance To Begin CLINICAL STUDY OF PARKINSON'S DISEASE TREATMENT - Aug. 24, 2017

Titan Pharmaceuticals Inc. Just Filed Its Quarterly Report: 3. Net Income (Lo... - Aug. 9, 2017

Submission of Matters to a Vote of Security - Aug. 2, 2017

Titan Pharmaceuticals Secures $10 Million Debt Facility From Horizon Technology Finance - July 28, 2017

Titan Pharmaceuticals And Walter Reed Army Institute OF RESEARCH COLLABORATE TO EVALUATE PRONEURA ANTIMALARIAL IMPLANTS - July 6, 2017

Titan Pharmaceuticals Inc. releases salary data. CEO sees compensation fall -10% - June 26, 2017

Titan Pharmaceuticals Corporate Presentation May 2017 © 2017 Titan Pharmaceuticals Inc. Nasdaq:Ttnp - June 6, 2017

Titan Pharmaceuticals Inc. Just Filed Its Quarterly Report: 3. Net Loss Per S... - May 10, 2017

Statement of acquisition of beneficial ownership by individuals - April 19, 2017

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: Net Income (Loss... - March 16, 2017

Titan Pharmaceuticals Corporate Presentation March 2017 © 2017 Titan Pharmaceuticals Inc. Nasdaq:Ttnp - March 10, 2017

Titan Pharmaceuticals Receives Fda Communication On ROPINIROLE IMPLANT INVESTIGATIONAL NEW DRUG APPLICATION - Feb. 28, 2017

On February - Feb. 27, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Feb. 21, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Feb. 21, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Feb. 21, 2017

Titan Pharmaceuticals Inc. director was just granted 10,000 options - Feb. 21, 2017

Titan Pharmaceuticals Inc.'s President and CEO was just granted 80,000 options - Feb. 14, 2017

Kevin Kotler just issued a filing suggesting it has sold all of its Titan Pharmaceuticals Inc. - Feb. 10, 2017

Titan Pharmaceuticals Corporate Presentation January 2017 © 2017 Titan Pharmaceuticals Inc. Nasdaq:Ttnp - Jan. 9, 2017

Titan Pharmaceuticals Inc. director just declared 5,000 options - Jan. 6, 2017

Titan Pharmaceuticals Inc. director just declared 25,000 options - Jan. 6, 2017

Titan Pharmaceuticals Appoints Two New Board Members - Jan. 4, 2017

Titan Pharmaceuticals Corporate Presentation Sunil Bhonsle November 2016 © 2016 Titan Pharmaceuticals Inc. Nasdaq:Ttnp - Nov. 16, 2016

Titan Pharmaceuticals Inc. Just Filed Its Quarterly Report: 3. Net Income (Los... - Nov. 9, 2016

Departure of Directors or Certain - Sept. 30, 2016

Entry into Material Definitive - Sept. 1, 2016

Prospectus [Rule 424(b)(5)] - Sept. 1, 2016

Titan Pharmaceuticals Corporate Presentation  Sunil Bhonsle  August 2016 © 2016 Titan Pharmaceuticals Inc.  Nasdaq:Ttnp - Aug. 31, 2016

Titan Pharmaceuticals Inc. Just Filed Its Quarterly Report: 3. Net Income (Los... - Aug. 9, 2016

Departure of Directors or Certain - Aug. 3, 2016

Titan Pharmaceuticals Inc. director just picked up 13,000 shares - July 19, 2016

Titan Pharmaceuticals Inc.'s President and CEO just picked up 10,000 shares - July 19, 2016

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. Robert E. Mead 1,754,546 N/A Nov. 10, 2015
2. RENAISSANCE TECHNOLOGIES LLC 704,600 N/A Sept. 30, 2018
3. PERKINS CAPITAL MANAGEMENT INC 545,000 0.1 Dec. 31, 2018
4. BlackRock Fund Advisors 513,014 N/A Sept. 30, 2016
5. VANGUARD GROUP INC 432,337 N/A Sept. 30, 2018
6. GEODE CAPITAL MANAGEMENT, LLC 341,474 N/A Dec. 31, 2018
7. BNP PARIBAS ARBITRAGE, SA 193,997 N/A Dec. 31, 2017
8. MORGAN STANLEY 169,501 N/A Dec. 31, 2016
9. BlackRock Institutional Trust Company, N.A. 131,115 N/A Dec. 31, 2016
10. BlackRock Investment Management, LLC 71,414 N/A Dec. 31, 2016
11. NORTHERN TRUST CORP 52,639 N/A March 31, 2018
12. BANK OF AMERICA CORP /DE/ 36,864 N/A Sept. 30, 2017
13. CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 28,073 N/A Dec. 31, 2018
14. SUSQUEHANNA INTERNATIONAL GROUP, LLP 11,939 N/A Dec. 31, 2017
15. TWO SIGMA SECURITIES, LLC 11,508 N/A Dec. 31, 2018
16. BlackRock Advisors LLC 11,277 N/A Sept. 30, 2016
17. Cutter & CO Brokerage, Inc. 10,000 N/A Dec. 31, 2018
18. BRONFMAN E.L. ROTHSCHILD, L.P. 8,235 N/A Dec. 31, 2018
19. Blume Capital Management, Inc. 2,546 N/A Dec. 31, 2018
20. Vantage Investment Advisors, LLC 2,273 N/A Sept. 30, 2018
21. MetLife Securities, Inc 1,383 N/A Dec. 31, 2016
22. BlackRock Inc. 644 N/A Sept. 30, 2016
23. WELLS FARGO & COMPANY/MN 550 N/A Sept. 30, 2018
24. UBS Group AG 237 N/A Dec. 31, 2017
25. DEUTSCHE BANK AG\ 88 N/A Dec. 31, 2017
26. HUNTINGTON NATIONAL BANK 87 N/A March 31, 2019
27. JPMORGAN CHASE & CO 35 N/A Sept. 30, 2017
28. SIMPLEX TRADING, LLC 33 N/A Dec. 31, 2018
29. LADENBURG THALMANN FINANCIAL SERVICES INC 2 N/A Sept. 30, 2017

Titan Pharmaceuticals Inc. (TTNP)

140

cctranscripts

April 16, 2019

Registration statement under Securities Act of 1933 http://www.conferencecalltranscripts.org/pink/summary?id=6060817

cctranscripts

April 5, 2019

Registration statement under Securities Act of 1933 http://www.conferencecalltranscripts.org/pink/summary?id=6024071

cctranscripts

April 3, 2019

Titan Pharmaceuticals Inc.'s Executive Chairman was just granted 200,000 options http://www.conferencecalltranscripts.org/pink/summary?id=6011761

cctranscripts

April 3, 2019

Titan Pharmaceuticals Inc.'s President and CEO was just granted 200,000 options http://www.conferencecalltranscripts.org/pink/summary?id=6011769

cctranscripts

April 3, 2019

Departure of Directors or Certain http://www.conferencecalltranscripts.org/pink/summary?id=6011816

cctranscripts

April 2, 2019

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: 14. Subsequent Event... http://www.conferencecalltranscripts.org/pink/summary?id=6000648

cctranscripts

April 1, 2019

Titan Pharmaceuticals Inc. Just Filed Its Annual Report: 14. Subsequent Event... http://www.conferencecalltranscripts.org/pink/summary?id=5996066

cctranscripts

Feb. 25, 2019

Departure of Directors or Certain http://www.conferencecalltranscripts.org/pink/summary?id=5825399

cctranscripts

Feb. 25, 2019

Titan Pharmaceuticals Inc.'s See Remarks just declared 41,667 options http://www.conferencecalltranscripts.org/pink/summary?id=5826967

cctranscripts

Feb. 25, 2019

Titan Pharmaceuticals Inc.'s Chief Scientific Officer just declared owning 2,387 shares of Titan Pharmaceuticals Inc. http://www.conferencecalltranscripts.org/pink/summary?id=5826936

cctranscripts

Feb. 14, 2019

Regulation FD http://www.conferencecalltranscripts.org/pink/summary?id=5778997

cctranscripts

Jan. 25, 2019

Titan Pharmaceuticals Announces Reverse Stock Split http://www.conferencecalltranscripts.org/pink/summary?id=5694060

cctranscripts

Dec. 20, 2018

Titan Pharmaceuticals Inc. releases salary data. CEO sees compensation fall -16% http://www.conferencecalltranscripts.org/pink/summary?id=5601859

cctranscripts

Dec. 6, 2018

Other preliminary proxy statements http://www.conferencecalltranscripts.org/pink/summary?id=5557709

cctranscripts

Oct. 22, 2018

Titan Pharmaceuticals Inc. director just picked up 200,000 shares http://www.conferencecalltranscripts.org/pink/summary?id=5406203

cctranscripts

Oct. 22, 2018

Type of filing Current report, item 8.01 not supported http://www.sec.gov/Archives/edgar/data/910267/000114420418054795/0001144204-18-054795-index.htm

cctranscripts

Oct. 3, 2018

On October http://www.conferencecalltranscripts.org/pink/summary?id=5359726

cctranscripts

Sept. 26, 2018

Titan Pharmaceuticals Inc. director just picked up 500,000 shares http://www.conferencecalltranscripts.org/pink/summary?id=5334400

cctranscripts

Sept. 25, 2018

Titan Pharmaceuticals Inc.'s Executive Chairman just picked up 400,000 shares http://www.conferencecalltranscripts.org/pink/summary?id=5330526

cctranscripts

Sept. 25, 2018

Titan Pharmaceuticals Inc. director just picked up 80,000 shares http://www.conferencecalltranscripts.org/pink/summary?id=5330541
 


Feedback